5,740 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 5,740 shares of the company’s stock, valued at approximately $203,000.

A number of other hedge funds also recently made changes to their positions in the business. Concurrent Investment Advisors LLC bought a new stake in shares of Dyne Therapeutics during the 1st quarter worth about $573,000. Sei Investments Co. bought a new position in shares of Dyne Therapeutics during the first quarter worth approximately $693,000. Rafferty Asset Management LLC lifted its holdings in Dyne Therapeutics by 17.7% during the 4th quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock worth $2,182,000 after purchasing an additional 24,632 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Dyne Therapeutics during the 1st quarter worth approximately $810,000. Finally, Commodore Capital LP bought a new stake in Dyne Therapeutics in the 4th quarter valued at $11,970,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on DYN shares. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Oppenheimer restated an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Morgan Stanley lifted their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, Guggenheim increased their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $33.83 on Monday. Dyne Therapeutics, Inc. has a 52 week low of $6.40 and a 52 week high of $47.45. The stock has a fifty day moving average of $40.26 and a 200-day moving average of $33.93. The stock has a market capitalization of $2.96 billion, a P/E ratio of -8.52 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, research analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In related news, CEO John Cox purchased 32,000 shares of the stock in a transaction dated Wednesday, September 4th. The stock was bought at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now owns 8,000 shares of the company’s stock, valued at $264,320. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CEO John Cox purchased 32,000 shares of Dyne Therapeutics stock in a transaction dated Wednesday, September 4th. The shares were bought at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Susanna Gatti High sold 8,976 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the transaction, the chief operating officer now owns 131,636 shares of the company’s stock, valued at approximately $4,529,594.76. The disclosure for this sale can be found here. Insiders sold a total of 135,304 shares of company stock valued at $4,857,019 in the last quarter. Insiders own 20.77% of the company’s stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.